IV Immunoglobulin (IVig) has yet to take off as a major therapy for MS, but it has shown promise. Here, a study shows that the administration of IVig after the first clinically significant event that might indicate MS reduces the chance of developing a second event.

"Intravenous immunoglobulin (IVIg) has been reported to reduce disease activity in patients with relapsing-remitting multiple sclerosis...

Intravenous immunoglobulin treatment for the first year from onset of the first neurological event suggestive of demyelinative disease significantly lowers the incidence of a second attack and reduces disease activity as measured by brain magnetic resonance imaging."

Click "read more" for the full abstract...